Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.56 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.51 |
| ▸ | NOS2 | P35228 | 6/20 | 0.50 |
| ▸ | NOS1 | P29475 | 6/20 | 0.50 |
| ▸ | NOS3 | P29474 | 5/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 4/20 | 0.44 |
| ▸ | ARG1 | P05089 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL29778163 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL7928810 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL30361345 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL31663499 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL6374054 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL1790 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL28759066 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL288132 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL1791 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL2411547 | 1.00 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119959442-A | Liquid chromatography tandem mass spectrometry detection method for simultaneously detecting NMN, succinic acid, GABA, glutamine, arginine and citrulline in various samples | 上海交通大学医学院附属新华医院 | 2025-05-09 | — | — | CN | claimed |
| US-12469688-B2 | Reaction monitoring | PURDUE RESEARCH FOUNDATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250340863-A1 | POLYPEPTIDE-ENCODED LIBRARY AND SCREENING METHOD USING SAME | WHOLESOME FUTURE LTD (KY) | 2025-11-06 | — | — | US | disclosed |
| US-20250314666-A1 | DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDERS BASED ON AMINE CONTAINING METABOTYPES | STEMINA BIOMARKER DISCOVERY INC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4313114-B1 | COMBINED TREATMENT OF BRAIN INJURY | CHIESI FARM SPA (IT) | 2025-09-17 | — | — | EP | disclosed |
| US-12365903-B2 | Application of aptamer in recognition and binding of alkaline phosphatase heterodimer or tumor detection | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-07-22 | — | — | US | disclosed |
| CN-119959442-A | Liquid chromatography tandem mass spectrometry detection method for simultaneously detecting NMN, succinic acid, GABA, glutamine, arginine and citrulline in various samples | 上海交通大学医学院附属新华医院 | 2025-05-09 | — | — | CN | disclosed |
| CN-119881145-A | Liquid chromatography tandem mass spectrometry method for measuring multiple amino acids | 上海市徐汇区中心医院 | 2025-04-25 | — | — | CN | disclosed |
| EP-4534742-A2 | POLYPEPTIDE-ENCODED LIBRARY AND SCREENING METHOD USING SAME | Wholesome Future Limited (KY) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025043178-A1 | COMPOSITIONS AND METHODS FOR INCREASING ARGININE AND NITRIC OXIDE LEVELS | VIREO SYSTEMS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-11723932-B2 | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | SYNLOGIC OPERATING COMPANY, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| CN-116121254-A | Aptamer for recognizing and binding cellular prion protein and application thereof | 中国科学院化学研究所 | 2023-05-16 | — | — | CN | disclosed |
| WO-2022241228-A2 | VARIANTS OF SIRT6 FOR USE IN PREVENTING AND/OR TREATING AGE-RELATED DISEASES | UNIVERSITY OF ROCHESTER (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022200550-A1 | COMBINED TREATMENT OF BRAIN INJURY | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-09-29 | — | — | WO | disclosed |
| US-20220199383-A1 | REACTION MONITORING | PURDUE RESEARCH FOUNDATION | 2022-06-23 | — | — | US | disclosed |
| US-11351156-B2 | Combination treatment of pancreatic cancer | INSERM (FR) | 2022-06-07 | — | — | US | disclosed |
| WO-2022115350-A1 | ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115344-A1 | ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115343-A1 | ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-11309172-B2 | Reaction monitoring | PURDUE RESEARCH FOUNDATION (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723932-B2 | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | PDCD1, CD274, PDCD4 | OTC 3560/4885DDAH1 3171/4885NOS2 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.